| Date | Time | Source | Headline | Symbol | Company |
| 05/29/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 05/24/2024 | 4:46PM | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 05/16/2024 | 6:05AM | Edgar (US Regulatory) | Form DEFR14A - Revised definitive proxy soliciting materials | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 05/14/2024 | 6:45AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 05/14/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 05/14/2024 | 6:32AM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 05/08/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 05/07/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024 | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 03/27/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 03/20/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 03/14/2024 | 8:52AM | GlobeNewswire Inc. | Cellectar Biosciences to Present at the 36th Annual Roth Conference | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 03/04/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 02/14/2024 | 8:31PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 02/14/2024 | 4:29PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 02/07/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 02/02/2024 | 6:03AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 01/31/2024 | 8:00AM | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 01/30/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 01/25/2024 | 4:30PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 01/25/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 01/22/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 01/16/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 01/12/2024 | 6:44AM | GlobeNewswire Inc. | Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 01/11/2024 | 6:40AM | GlobeNewswire Inc. | Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 01/09/2024 | 6:02AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 01/08/2024 | 6:30AM | GlobeNewswire Inc. | Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 01/03/2024 | 8:30AM | GlobeNewswire Inc. | Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024 | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 12/19/2023 | 8:30AM | GlobeNewswire Inc. | Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 12/12/2023 | 8:09PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CLRB | Cellectar Biosciences Inc |
| 12/12/2023 | 8:07PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CLRB | Cellectar Biosciences Inc |